Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keac513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 Vaccination in Patients With Systemic Lupus Erythematosus: Adverse Events and Rating Agreement of Flares Between Patients and Physicians.
Int J Rheum Dis
December 2024
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Objectives: To compare adverse events and flares among different doses and types of COVID-19 vaccines in patients with systemic lupus erythematosus (SLE).
Methods: All consecutive SLE patients in a lupus cohort, seen between March and October 2022, were invited to join this retrospective study. Inclusion criteria were aged ≥ 20 years and had received at least one dose of COVID-19 vaccine.
Ruptured Ovarian Cyst Leading to Massive Spontaneous Intraperitoneal Hemorrhage in Chronic Immune Thrombocytopenic Purpura (ITP): Successful Nonsurgical Intervention.
Cureus
August 2024
Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Article Synopsis
- A 25-year-old woman with immune thrombocytopenic purpura (ITP) presented with a spontaneous petechial rash, abdominal pain, and dizziness, indicating severe thrombocytopenia.
- Imaging revealed free fluid in the peritoneal cavity and a ruptured ovarian cyst, leading to significant internal bleeding.
- The patient was treated conservatively with platelet transfusions, steroids, and romiplostim to manage her severe bleeding and ITP relapse.
Treatment of Behçet disease with oral roflumilast: an observational study.
Clin Exp Dermatol
December 2024
Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain.
Background: Mucocutaneous Behçet disease often presents a therapeutic challenge. Roflumilast has shown promise in the treatment of other inflammatory dermatological conditions.
Objectives: The objective of this study was to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet disease-associated aphthosis in routine clinical practice.
Kidney histopathology in predicting flares following drug withdrawal in proliferative lupus nephritis in clinical remission.
Rheumatol Int
December 2024
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Fourth Floor SSB, Puducherry, India.
Residual renal histopathological activity at clinical remission in Proliferative Lupus Nephritis (PLN) can predict renal flare upon immunosuppression withdrawal. Data on the role of histological renal remission in predicting extra-renal flares is lacking. We assessed renal histopathology prior to drug withdrawal and the occurrence of renal and extra-renal flares over 52 weeks after drug withdrawal in PLN patients in long-term clinical remission.
View Article and Find Full Text PDFShort- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico.
Lupus
April 2023
Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
Objective: To determine if SARS-CoV-2 mRNA vaccination has an impact on the clinical course of systemic lupus erythematosus (SLE).
Methods: Puerto Ricans with SLE who received mRNA COVID-19 vaccines were studied. Demographic parameters, clinical manifestations, disease activity (per Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), disease damage (per Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), emergency room visits, hospitalizations, and pharmacologic therapy were determined.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!